DNA vaccine trial aims to train immune system against hepatitis c
NCT ID NCT02772003
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 44 times
Summary
This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through injection and a brief electrical pulse to help cells take up the DNA.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
University of Puerto Rico
San Juan, 00936, Puerto Rico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNA vaccine (INO-8000) with an immune booster (INO-9012) given via injection and electroporation
What this could lead to
If it works, this could point toward a treatment that helps the immune system control chronic hepatitis C, potentially reducing the risk of liver cancer.
What could go wrong
This is a very early phase I trial with only 33 participants, so safety and dosing are the main focus. The vaccine may not produce a strong enough immune response, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.